Keros Therapeutics, Inc.
KROS
$9.93
-$0.14-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -99.83% | -87.34% | 3,575.77% | 49,002.70% | 254,413.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.83% | -87.34% | 3,575.77% | 49,002.70% | 254,413.25% |
| Cost of Revenue | -66.95% | -60.97% | -60.35% | 7.38% | 27.32% |
| Gross Profit | -109.68% | 59.08% | 89.24% | 37.41% | 525.77% |
| SG&A Expenses | -3.33% | 10.11% | 3.13% | 45.39% | 1.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.67% | -47.50% | -49.79% | 14.88% | 21.91% |
| Operating Income | -117.02% | 45.22% | 73.77% | 21.06% | 413.59% |
| Income Before Tax | -114.96% | 45.38% | 83.56% | 27.26% | 467.62% |
| Income Tax Expenses | -- | -604.67% | -- | -- | -- |
| Earnings from Continuing Operations | -115.97% | 49.03% | 86.25% | 32.17% | 444.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -115.97% | 49.03% | 86.25% | 32.17% | 444.32% |
| EBIT | -117.02% | 45.22% | 73.77% | 21.06% | 413.59% |
| EBITDA | -116.72% | 45.64% | 74.31% | 21.32% | 416.11% |
| EPS Basic | -133.00% | 24.40% | 87.28% | 39.70% | 402.94% |
| Normalized Basic EPS | -130.91% | 19.32% | 84.79% | 35.34% | 423.44% |
| EPS Diluted | -133.43% | 24.40% | 87.23% | 39.37% | 399.17% |
| Normalized Diluted EPS | -131.26% | 19.32% | 84.79% | 35.34% | 419.80% |
| Average Basic Shares Outstanding | -51.60% | -32.57% | 8.07% | 12.49% | 13.66% |
| Average Diluted Shares Outstanding | -52.15% | -32.57% | 8.07% | 12.49% | 14.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |